Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical TrialJ. Andrew Bird, A. Wesley Burks, Amal Assa’ad et al.|The Journal of Allergy and Clinical Immunology In Practice|2017Cited by 200
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On StudyBrian P. Vickery, Dareen Siri, Andrea Vereda et al.|The Journal of Allergy and Clinical Immunology In Practice|2020Cited by 89